Mantle cell lymphoma

It is a cancer of B cells — the white blood cells that normally make antibodies — named for the mantle zone, the ring of cells around the outside of a lymph node follicle where these cells normally sit.

It is classified near the slow-growing lymphomas, but it mostly does not behave like one. The NCI reports that 80% of people present with disease that is behaving aggressively.

A minority have a slower-growing form that involves the blood and marrow rather than the lymph nodes, and that may need no treatment for a long time. How large that minority is depends on which source you read, so we are not going to put a number on it.

Lymphoma Action describes the awkward hybrid honestly: it usually grows quickly, like a fast-growing lymphoma, and it is also likely to come back after treatment and need more, like a slow-growing one.

It is uncommon. Lymphoma Action puts UK diagnoses at around 600 a year, though the page does not state which year that count comes from.

None of the sources we read states a cause. We are treating that as unanswered rather than filling it in.

The World Health Organization’s classification separates the leukaemic non-nodal form from the conventional form. That is a distinction in how the disease is categorised, not an explanation of why anyone gets it.

Nothing in these sources supports a lifestyle, diet, stress or exposure explanation, and the sources do not report on inheritance or family risk.

Behaviour splits in two, and which side someone is on shapes everything that follows.

Most people present with disease that is growing quickly, often already widespread by the time it is found, and treatment starts soon after diagnosis rather than after a period of monitoring.

A minority have the slow non-nodal form, which involves the blood and marrow, and for those people watching rather than treating can be the right first step.

Like the slow-growing lymphomas, it tends to relapse and need further lines of treatment over time. That combination — grows fast, comes back — is what makes it its own thing rather than a version of something else.

First-line treatment for advanced disease is chemotherapy combined with an antibody drug such as rituximab.

Added to that, increasingly, is a BTK inhibitor. BTK — Bruton tyrosine kinase — is a signalling protein that B cells depend on, and blocking it starves the lymphoma cells. Ibrutinib, acalabrutinib and zanubrutinib are the ones named for this disease. They are tablets taken on an ongoing basis rather than a course with an end date.

The TRIANGLE trial found that adding ibrutinib to first-line treatment improved outcomes substantially in people aged 18 to 65: three-year failure-free survival of 88% with it, against 72% without.

And here is where the transplant story changes. For fit younger people, intensive chemotherapy followed by an autologous transplant — the person’s own cells — has been the traditional consolidation. When ibrutinib is part of the regimen, TRIANGLE did not show that adding the transplant improved outcomes, and a second trial, ECOG 4151, found no difference in three-year overall survival between people who had an autologous transplant and those who did not.

That needs a careful reading in both directions. TRIANGLE tested whether the transplant arm was better and found it was not; failing to show superiority is not the same as proving the two are equivalent. EBMT’s 2025 recommendations put it as trials "questioning the benefit" of first-line autologous consolidation — questioning, not settling. Practice varies by country and by centre, and if your team has recommended a transplant, nothing here says they are wrong.

For people whose disease comes back, BTK inhibitors are the most common next treatment. CAR T-cell therapy is available after at least two prior treatments, and it is made from the patient’s own T cells.

People with the slow non-nodal form and no symptoms may be watched rather than treated.

Most people are diagnosed at an advanced stage and start treatment quickly, without the period of monitoring that people with the slower lymphomas often have.

For fit younger people the traditional path has meant intensive chemotherapy followed by an autologous transplant — a hospital stay, a stretch with almost no immune system, and a long recovery. That people may increasingly be spared this is a genuinely meaningful part of the story, and it is worth knowing it is being actively debated rather than settled.

Maintenance treatment can continue long after the acute phase ends. Lymphoma Action describes maintenance rituximab after a transplant running every two months for up to three years.

BTK inhibitors reframe the experience again: from a course of treatment with an end date to a medication you stay on, with the cost, access and side-effect questions that brings.

And because it tends to come back, most people face the question of a next line of treatment at some point.

The transplant discussed in mantle cell lymphoma is autologous — the patient’s own stem cells, collected before high-dose chemotherapy and returned afterwards. No donor and no match.

That distinction matters more here than almost anywhere, because "transplant" comes up early in this disease and a reader who hears it as "I need to find a donor" has been misled.

A donor transplant does exist as an option, and EBMT places it clearly: for people without access to CAR T-cell therapy, or who have had CAR-T and it has not worked. That is late, selective, and dependent on what is available where someone lives.

CAR-T itself involves no donor. The products approved for this disease are made from the patient’s own T cells.

And the direction of travel is worth naming. As targeted drugs have moved into first-line treatment, the transplant question in mantle cell lymphoma has moved further away rather than closer.